Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences, Inc. (RNA) Common Equity (2019 - 2025)

Avidity Biosciences' Common Equity history spans 7 years, with the latest figure at $1.7 billion for Q4 2025.

  • For Q4 2025, Common Equity rose 18.5% year-over-year to $1.7 billion; the TTM value through Dec 2025 reached $1.7 billion, up 18.5%, while the annual FY2025 figure was $1.7 billion, 18.5% up from the prior year.
  • Common Equity reached $1.7 billion in Q4 2025 per RNA's latest filing, down from $1.9 billion in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $1.9 billion in Q3 2025 to a low of $264.5 million in Q2 2021.
  • Average Common Equity over 5 years is $812.2 million, with a median of $559.0 million recorded in 2023.
  • The largest YoY upside for Common Equity was 503.19% in 2021 against a maximum downside of 19.93% in 2021.
  • A 5-year view of Common Equity shows it stood at $381.4 million in 2021, then skyrocketed by 51.55% to $578.1 million in 2022, then decreased by 13.37% to $500.8 million in 2023, then surged by 184.56% to $1.4 billion in 2024, then increased by 18.5% to $1.7 billion in 2025.
  • Per Business Quant, the three most recent readings for RNA's Common Equity are $1.7 billion (Q4 2025), $1.9 billion (Q3 2025), and $1.2 billion (Q2 2025).